KR920700671A - 종양세포 증식 억제제 - Google Patents
종양세포 증식 억제제Info
- Publication number
- KR920700671A KR920700671A KR1019910700779A KR910700779A KR920700671A KR 920700671 A KR920700671 A KR 920700671A KR 1019910700779 A KR1019910700779 A KR 1019910700779A KR 910700779 A KR910700779 A KR 910700779A KR 920700671 A KR920700671 A KR 920700671A
- Authority
- KR
- South Korea
- Prior art keywords
- cell proliferation
- tumor cell
- proliferation inhibitor
- residue
- oligopeptide
- Prior art date
Links
- 230000004663 cell proliferation Effects 0.000 title claims description 6
- 239000003112 inhibitor Substances 0.000 title claims description 6
- 210000004881 tumor cell Anatomy 0.000 title claims description 5
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 4
- 102000015636 Oligopeptides Human genes 0.000 claims 4
- 108010038807 Oligopeptides Proteins 0.000 claims 4
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims 4
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims 4
- 229940061720 alpha hydroxy acid Drugs 0.000 claims 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims 2
- 238000009833 condensation Methods 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 238000006116 polymerization reaction Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 본 발명으 종양세포증식 억제제의 투여량에 대한 생존율이 관계를 나타내는 선도이다.
Claims (4)
- α-히드록시산의 저 축합물 및 중합물, 피로글루탐산을 적어도 1 잔기 함유하는 올리고펩티드 및 안정화제를 포함하는 종양세포 증식 억제제.
- 제1항에 있어서, α-히드록시산의 저 축합 및 중합물이 주로 α-히드록시산의 2내지 10분자를 축합 및 중합한 화합물과 그 금속염을 포함하는 종양세포 증식 억제제.
- 제1항에 있어서, 피로글루탐산을 적어도 1 잔기 함유하는 올리고펩티드가 2내지 8잔기의 아미노산으로 이루는 올리고펩티드이고 피로글루탐산을 적어도 1잔기 함유되는 화합물 및 그 금속염을 포함하는 종양 세포 증식 억제제.
- 제1항에 있어서, 그 구성성분증량비가 α-히드록시산의 저 축합물 및 중합물 10, 피로글루탐산을 적어도 1잔기 함유하는 올리고펩티드 1내지 4, 안정화제(당, 당알콜) 1내지 3인 종양 세포증식 억제제.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1332870A JP2997488B2 (ja) | 1989-12-25 | 1989-12-25 | 腫瘍細胞増殖抑制剤 |
JP1-332870 | 1989-12-25 | ||
PCT/JP1990/001678 WO1991009612A1 (fr) | 1989-12-25 | 1990-12-21 | Inhibiteur de croissance de cellules tumorales |
Publications (1)
Publication Number | Publication Date |
---|---|
KR920700671A true KR920700671A (ko) | 1992-08-10 |
Family
ID=18259725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019910700779A KR920700671A (ko) | 1989-12-25 | 1990-12-21 | 종양세포 증식 억제제 |
Country Status (13)
Country | Link |
---|---|
US (1) | US5972879A (ko) |
EP (1) | EP0460232B1 (ko) |
JP (1) | JP2997488B2 (ko) |
KR (1) | KR920700671A (ko) |
AT (1) | ATE164075T1 (ko) |
AU (1) | AU635802B2 (ko) |
CA (1) | CA2044621A1 (ko) |
DE (1) | DE69032158T2 (ko) |
DK (1) | DK0460232T3 (ko) |
ES (1) | ES2113370T3 (ko) |
NO (1) | NO913322D0 (ko) |
RU (1) | RU2034564C1 (ko) |
WO (1) | WO1991009612A1 (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2385318A1 (en) | 1999-09-20 | 2001-03-29 | Amato Pharmaceutical Products, Ltd. | Method for producing cyclic lactic acid oligomer |
JP2002275256A (ja) * | 2001-03-19 | 2002-09-25 | Tendou Seiyaku Kk | 乳酸オリゴマーの製造方法 |
RU2283654C1 (ru) * | 2005-03-30 | 2006-09-20 | Борис Владимирович Афанасьев | Способ получения ростовых факторов белковой природы, ростовой фактор белковой природы и ингибитор пролиферации фибробластов |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4211769A (en) * | 1977-08-24 | 1980-07-08 | Takeda Chemical Industries, Ltd. | Preparations for vaginal administration |
EP0115472A3 (de) * | 1983-01-27 | 1985-10-02 | Ciba-Geigy Ag | Pyrrolidinonderivate und Verfahren zu ihrer Herstellung |
FI840261A (fi) * | 1983-01-27 | 1984-07-28 | Ciba Geigy Ag | Substituerade pyrrolidinonderivat och foerfarande foer deras framstaellning. |
EP0127426A1 (en) * | 1983-05-23 | 1984-12-05 | Takeda Chemical Industries, Ltd. | Percutaneous pharmaceutical compositions for external use |
JPS6023326A (ja) * | 1983-07-18 | 1985-02-05 | Takeda Chem Ind Ltd | ペプチド含有経口投与製剤 |
DE3428372A1 (de) * | 1984-08-01 | 1986-02-13 | Hoechst Ag, 6230 Frankfurt | Mikrokapseln von regulatorischen peptiden mit kontrollierter freisetzung, verfahren zu ihrer herstellung und injektionszubereitungen |
JPS6163613A (ja) * | 1984-09-04 | 1986-04-01 | Mitsui Toatsu Chem Inc | 顆粒状に調整された徐放性製剤 |
-
1989
- 1989-12-25 JP JP1332870A patent/JP2997488B2/ja not_active Expired - Fee Related
-
1990
- 1990-12-21 ES ES91900944T patent/ES2113370T3/es not_active Expired - Lifetime
- 1990-12-21 EP EP91900944A patent/EP0460232B1/en not_active Expired - Lifetime
- 1990-12-21 CA CA002044621A patent/CA2044621A1/en not_active Abandoned
- 1990-12-21 KR KR1019910700779A patent/KR920700671A/ko not_active Application Discontinuation
- 1990-12-21 AT AT91900944T patent/ATE164075T1/de not_active IP Right Cessation
- 1990-12-21 DE DE69032158T patent/DE69032158T2/de not_active Expired - Fee Related
- 1990-12-21 WO PCT/JP1990/001678 patent/WO1991009612A1/ja active IP Right Grant
- 1990-12-21 US US07/700,158 patent/US5972879A/en not_active Expired - Fee Related
- 1990-12-21 DK DK91900944.9T patent/DK0460232T3/da active
- 1990-12-21 AU AU69127/91A patent/AU635802B2/en not_active Ceased
-
1991
- 1991-08-23 RU SU915010005A patent/RU2034564C1/ru not_active IP Right Cessation
- 1991-08-23 NO NO913322A patent/NO913322D0/no unknown
Also Published As
Publication number | Publication date |
---|---|
WO1991009612A1 (fr) | 1991-07-11 |
DE69032158T2 (de) | 1998-08-06 |
US5972879A (en) | 1999-10-26 |
ES2113370T3 (es) | 1998-05-01 |
NO913322L (no) | 1991-08-23 |
DE69032158D1 (de) | 1998-04-23 |
CA2044621A1 (en) | 1991-06-26 |
RU2034564C1 (ru) | 1995-05-10 |
ATE164075T1 (de) | 1998-04-15 |
JPH03193731A (ja) | 1991-08-23 |
AU635802B2 (en) | 1993-04-01 |
JP2997488B2 (ja) | 2000-01-11 |
EP0460232A4 (en) | 1993-03-17 |
DK0460232T3 (da) | 1998-04-14 |
EP0460232A1 (en) | 1991-12-11 |
EP0460232B1 (en) | 1998-03-18 |
NO913322D0 (no) | 1991-08-23 |
AU6912791A (en) | 1991-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR910000802A (ko) | 흡수성 수지의 제조방법 | |
KR840002416A (ko) | 신규 아크릴 공중합체의 제조방법 | |
RU94009853A (ru) | Способ извлечения карболированного продукта | |
KR950702714A (ko) | 포지티브 작용성 방사선 민감성 혼합물 및 이로부터 제조된 기록물질 (Positive-acting radiation-sensitive mixture and recording material produced therewith) | |
KR880009635A (ko) | r-글로불린 주사용 용액 | |
KR830010142A (ko) | 안정화된 열경화성 에틸렌성 불포화 에폭시 에스테르 수지 조성물 | |
HUT54655A (en) | Process for producing substituted (quinolin-2-ylmethoxy)-phenylacyl sulfonamides and cyanamides, as well as pharmaceutical compositions comprising same | |
KR920700671A (ko) | 종양세포 증식 억제제 | |
KR890014783A (ko) | 금속표면 처리방법 | |
KR890005195A (ko) | 블록화된 산촉매 | |
KR840004120A (ko) | 아즈렌 유도체의 안정화 아즈렌 유도체의 안정화방법 | |
KR910011869A (ko) | 결정형 발프로산 마그네슘 및 그 제조방법 | |
KR910007943A (ko) | N-디클로로포스포릴트리클로로포스파젠 및 그의 중축합 생성물의 불순물의 해로운 영향 보완 방법. | |
KR930700404A (ko) | 1,4-비스(4-플루오로벤조일)벤젠의 제조 방법 | |
Martinez et al. | Corrosion Inhibitors | |
KR930021176A (ko) | 피록시캄 정 및 그의 제조방법 | |
JPS5592316A (en) | Cholesterol-lowering agent | |
KR900006431A (ko) | 분말 피복 수지조성물 | |
KR890007101A (ko) | 열방성 액정 중합체 | |
GB1157741A (en) | A process for the manufacture of Aminomethylene-Malononitrile | |
KR870002051A (ko) | L-페닐 알라닌 에스테르의 제조 방법 | |
Grahl-Nielsen et al. | Gas–liquid chromatographic separation of amino-acid derivatives | |
KR870007301A (ko) | 금속방식제 조성물 | |
ATE85972T1 (de) | Verfahren zur herstellung von methylhydrochinon. | |
KR830001203A (ko) | N-(1-메틸-2-필로리디닐-메틸)-2,3-디메톡시-5-메틸설파모일 벤즈아미드의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |